EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

UPCARE: Urinary Extracellular Vesicles‐Derived Prostate Cancer Assessment for Risk Evaluation

Shaoqin Jiang, Feiting Lu, Jiadi Chen, Yingzhen Jiao, Qingqing Qiu, Xinwen Nian, Min Qu, Yan Wang, Mengqiang Li, Fei Liu iD, Xu Gao

Journal of Extracellular Vesicles · 2024

DOI: 10.1002/jev2.12491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2024. Verfasst von Shaoqin Jiang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Extracellular Vesicles, Biomarkers, Tumor, Prostate-Specific Antigen. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Fujian Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the quest for efficient tumor diagnosis via liquid biopsy, extracellular vesicles (EVs) have shown promise as a source of potential biomarkers. This study addresses the gap in biomarker efficacy for predicting clinically significant prostate cancer (csPCa) between the Western and Chinese populations. We developed a urinary extracellular vesicles‐based prostate score (EPS) model, utilizing the EXODUS technique for EV isolation from 598 patients and incorporating gene expressions of FOXA1, PCA3, and KLK3. Our findings reveal that the EPS model surpasses prostate‐specific antigen (PSA) testing in diagnostic accuracy within a training cohort of 234 patients, achieving an area under the curve (AUC) of 0.730 compared to 0.659 for PSA ( p = 0.018). Similarly, in a validation cohort of 101 men, the EPS model achieved an AUC of 0.749, which was significantly better than PSA's 0.577 ( p < 0.001). Our model has demonstrated a potential reduction in unnecessary prostate biopsies by 26%, with only a 3% miss rate for csPCa cases, indicating its effectiveness in the Chinese population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsExtracellular VesiclesBiomarkers, TumorProstate-Specific AntigenMaleHumansMiddle AgedAgedRisk AssessmentHepatocyte Nuclear Factor 3-alphaKallikreinsAntigens, NeoplasmLiquid Biopsy

Stichwörter der Autor:innen

EPS modelEXODUS methodprostate cancerurinary extracellular vesicles

Substanzen

Biomarkers, TumorProstate-Specific AntigenHepatocyte Nuclear Factor 3-alphaFOXA1 protein, humanKallikreinsAntigens, Neoplasmprostate cancer antigen 3, humanKLK3 protein, human

Autor:innen und Institutionen

  • Department of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
  • Shenzhen Huixin Lifetechnologies Co., Ltd., Longhua, Shenzhen, Guangdong, China.
  • Department of Clinical Laboratory, Fujian Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
  • Department of Urology, Changhai Hospital, Shanghai, China.
  • Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Fei Liu

Förderung

  • Natural Science Foundation of Fujian Province
  • National Natural Science Foundation of China

Zitieren

APA

Jiang, S., Lu, F., Chen, J., Jiao, Y., Qiu, Q., Nian, X., Qu, M., Wang, Y., Li, M., Liu, F., & Gao, X. (2024). UPCARE: Urinary Extracellular Vesicles‐Derived Prostate Cancer Assessment for Risk Evaluation. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.12491

Vancouver

Jiang S, Lu F, Chen J, Jiao Y, Qiu Q, Nian X, et al. UPCARE: Urinary Extracellular Vesicles‐Derived Prostate Cancer Assessment for Risk Evaluation. Journal of Extracellular Vesicles. 2024. doi:10.1002/jev2.12491

BibTeX
@article{Jiang2024,
  author = {Jiang, Shaoqin and Lu, Feiting and Chen, Jiadi and Jiao, Yingzhen and Qiu, Qingqing and Nian, Xinwen and Qu, Min and Wang, Yan and Li, Mengqiang and Liu, Fei and Gao, Xu},
  title = {UPCARE: Urinary Extracellular Vesicles‐Derived Prostate Cancer Assessment for Risk Evaluation},
  journal = {Journal of Extracellular Vesicles},
  year = {2024},
  doi = {10.1002/jev2.12491}
}
Kostenlos starten →